List of Excipients in Branded Drug LYBALVI

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alkermes Inc	LYBALVI	olanzapine and samidorphan l-malate	65757-651	CELLULOSE, MICROCRYSTALLINE	2041-11-12
Alkermes Inc	LYBALVI	olanzapine and samidorphan l-malate	65757-651	CROSPOVIDONE	2041-11-12
Alkermes Inc	LYBALVI	olanzapine and samidorphan l-malate	65757-651	FERRIC OXIDE YELLOW	2041-11-12
Alkermes Inc	LYBALVI	olanzapine and samidorphan l-malate	65757-651	HYPROMELLOSE	2041-11-12
Alkermes Inc	LYBALVI	olanzapine and samidorphan l-malate	65757-651	LACTOSE MONOHYDRATE	2041-11-12

LYBALVI Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

LYBALVI is a fixed-dose oral combination of olanzapine and samidorphan developed to reduce olanzapine-associated weight gain while retaining olanzapine’s antipsychotic activity. Its excipient strategy is commercially important because the product combines a high-dose, established antipsychotic with a low-dose opioid-receptor antagonist in immediate-release tablets. The principal opportunities are generic formulation development, excipient and coating supply, differentiated oral delivery, manufacturing efficiency, and lifecycle extensions that preserve dose uniformity and pharmacokinetic comparability.

What is LYBALVI and how does its formulation work?

LYBALVI contains olanzapine and samidorphan in a fixed-dose tablet. Approved strengths are:

LYBALVI strength	Olanzapine	Samidorphan
5 mg/10 mg	5 mg	10 mg
10 mg/10 mg	10 mg	10 mg
15 mg/10 mg	15 mg	10 mg
20 mg/10 mg	20 mg	10 mg

The product is approved for:

• Schizophrenia in adults
• Bipolar I disorder, including acute manic or mixed episodes and maintenance monotherapy in adults

The tablet is administered once daily, with or without food. Samidorphan is an opioid-receptor antagonist intended to mitigate olanzapine-related weight gain. The fixed-dose architecture keeps samidorphan constant at 10 mg while varying olanzapine across four strengths.[1]

This design creates a formulation requirement that differs from a conventional single-active tablet. The manufacturing process must deliver:

1. Accurate low-dose samidorphan distribution within a substantially larger olanzapine dose range.
2. Consistent dissolution across all four strengths.
3. Physical stability for two active pharmaceutical ingredients with different dose levels and potentially different flow, compaction, and segregation behavior.
4. Robust coating performance for product identification and moisture protection.
5. Bioequivalence to a reference product with an established fixed-dose composition.

What excipients are used in LYBALVI tablets?

The U.S. prescribing information identifies the inactive ingredients as lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate. The film coating contains hypromellose, titanium dioxide, polyethylene glycol, talc, and colorants appropriate to tablet strength.[1]

Excipient category	Likely function in LYBALVI	Commercial relevance
Lactose monohydrate	Diluent and tablet-mass contributor	High-volume commodity demand; supplier qualification and grade selection are important
Microcrystalline cellulose	Diluent, dry binder, and compression aid	Supports direct compression and tablet robustness
Crospovidone	Superdisintegrant	Relevant to immediate-release performance and dissolution control
Colloidal silicon dioxide	Glidant and flow aid	Helps manage powder flow and segregation
Magnesium stearate	Lubricant	Over-lubrication can affect hardness and dissolution
Hypromellose	Film-forming coating polymer	Supports appearance, protection, and coating processability
Polyethylene glycol	Plasticizer and coating aid	Affects coating flexibility and process performance
Talc	Anti-tacking and coating aid	Supports high-throughput coating
Titanium dioxide and colorants	Opacity and product identification	Important for strength differentiation and supply continuity

The formulation uses common oral solid-dose excipients rather than a specialized lipid, polymeric, or modified-release platform. That limits exclusivity based solely on excipient identity. Commercial value is more likely to reside in excipient grade, quantitative composition, processing sequence, particle-size control, granulation or blending conditions, coating process parameters, and dissolution performance.

What excipient strategy is most important for LYBALVI?

The key strategy is low-dose uniformity within a fixed-dose combination.

Samidorphan is present at 10 mg in each tablet, while olanzapine ranges from 5 mg to 20 mg. A generic manufacturer must prevent samidorphan segregation during blending, transfer, compression, and tablet handling. Direct blending of samidorphan with a large quantity of olanzapine and diluent may create content-uniformity risk if particle size, density, or electrostatic properties differ materially.

Content-uniformity strategy

A commercial development program could evaluate:

• Ordered mixing or geometric dilution
• Pre-blending samidorphan with a portion of microcrystalline cellulose
• Co-milling or particle-size harmonization
• Wet granulation or dry granulation
• Separate granulation of active ingredients followed by final blending
• Low-shear and high-shear mixing conditions
• In-process sampling across blend locations and compression time points

The preferred process must meet USP content-uniformity requirements while avoiding excessive manufacturing complexity. A process that requires extensive segregation controls may reduce the cost advantage of a generic product.

Excipient-grade strategy

Excipient selection should focus on functional performance rather than nominal compendial identity. Important variables include:

• Lactose particle-size distribution and flow
• Microcrystalline cellulose moisture and compressibility
• Crospovidone swelling and wicking performance
• Colloidal silicon dioxide surface area and flow enhancement
• Magnesium stearate specific surface area and lubrication behavior
• Hypromellose viscosity grade
• Coating-system compatibility with tablet hardness and friability

Two formulations using the same listed excipients can produce materially different dissolution and tablet mechanical properties because of grade, supplier, particle size, moisture, and processing differences.

What formulation patents may protect LYBALVI?

LYBALVI’s relevant intellectual-property protection is likely to extend beyond the individual active ingredients. The principal protection categories are:

Protection category	Potential subject matter	Commercial impact
Fixed-dose composition	Olanzapine combined with samidorphan in specified ratios	Can delay or complicate ANDA entry
Dose architecture	Samidorphan fixed at 10 mg with multiple olanzapine strengths	May constrain strength-by-strength workarounds
Method of use	Treating schizophrenia or bipolar disorder while reducing olanzapine-associated weight gain	Creates litigation risk for labeled generic use
Manufacturing process	Blending, granulation, compression, or content-uniformity controls	Can create process patent exposure
Solid-state or particle properties	Polymorph, particle size, crystallinity, or physical mixtures	May affect non-infringing formulation options
Formulation performance	Dissolution, stability, or pharmacokinetic characteristics	Can narrow practical design-around space

The relevant patent review should distinguish composition claims from process and method-of-use claims. A formulation that avoids a composition claim may still face method-of-use exposure if an ANDA label includes the protected indication or weight-management-related language.

The Orange Book should be used to identify patents listed for LYBALVI and their expiration dates. FDA’s listing determines the formal patent-certification pathway for an ANDA, including Paragraph I, II, III, or IV certifications.[2] Patent databases and litigation dockets should then be used to determine claim scope, terminal disclaimers, continuations, and any settlements.

When does LYBALVI lose exclusivity?

LYBALVI received FDA approval on June 1, 2021. Samidorphan was a new active ingredient in the combination, giving the product a period of new chemical entity exclusivity under the applicable FDA framework. The practical competitive timeline depends on the interaction among regulatory exclusivity, Orange Book patents, pediatric exclusivity, and any litigation settlement.[1][2]

Exclusivity or barrier	Relevance to LYBALVI
New chemical entity exclusivity	Protects the new active ingredient from certain ANDA approvals for five years, subject to Paragraph IV timing rules
New clinical investigation exclusivity	May protect specific approval-supporting clinical studies for three years where applicable
Orange Book patents	May support Paragraph IV litigation and a 30-month stay of approval
Pediatric exclusivity	Could add six months if awarded for qualifying studies
Method-of-use patents	May permit approval with label carve-outs if the protected use can be omitted
Composition patents	Usually present the strongest barrier if claims cover the fixed-dose product directly

A commercial launch date cannot be determined from approval date alone. A generic applicant may file an ANDA before patent expiry and challenge listed patents through Paragraph IV certification. The outcome depends on patent expiration, litigation timing, claim construction, settlement terms, and whether a court grants an injunction.

Which companies are challenging LYBALVI?

The primary potential challengers are manufacturers with established CNS generic portfolios and oral-solid-dose manufacturing capacity. Likely candidate groups include:

• Large generic manufacturers with olanzapine experience
• Companies that already manufacture antipsychotic tablets
• Contract development and manufacturing organizations with low-dose combination expertise
• Specialty generic companies pursuing complex fixed-dose products
• International manufacturers seeking U.S. ANDA entry

Publicly attributable challenge activity should be assessed through FDA Paragraph IV notices, Hatch-Waxman complaints, district-court dockets, and Orange Book updates. A company may develop a bioequivalent product without publicly disclosing its program until it files an ANDA or triggers litigation.

What generic entry risks exist for LYBALVI?

Generic-entry risk is moderate to high over the long term but is technically more difficult than a conventional olanzapine generic.

Regulatory risks

The ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence. The principal regulatory issues are likely to include:

• Strength-specific content uniformity
• Samidorphan assay and impurity control
• Comparative dissolution for both active ingredients
• Stability of the fixed-dose tablet
• Analytical method specificity in the presence of olanzapine degradation products
• Manufacturing consistency across commercial-scale batches

Because olanzapine and samidorphan have different dose levels, a formulation that passes olanzapine testing but fails samidorphan uniformity would not be commercially viable.

Commercial risks

The reference product has an established prescriber proposition tied to weight gain. Generic substitution may be constrained if:

• Prescribers view the combination as clinically differentiated from olanzapine
• Payers prefer the lower-cost olanzapine monotherapy
• Patient access depends on formulary positioning
• The generic must preserve the fixed-dose combination rather than compete with separate products
• The label’s therapeutic and safety language limits substitution strategies

The strongest generic opportunity is likely to arise after the end of regulatory and patent barriers, when a manufacturer can offer a substantially lower acquisition cost while preserving the four-strength portfolio.

What commercial opportunities exist for excipient suppliers?

The excipient opportunity is concentrated in functional materials and qualified supply rather than novel chemical entities.

Immediate-release tablet excipients

Suppliers can target:

• Direct-compression lactose
• High-functionality microcrystalline cellulose
• Low-substituted or optimized crospovidone grades
• Flow-enhancing colloidal silicon dioxide
• Low-variability magnesium stearate
• Ready-to-use film-coating systems

A supplier with validated performance data can compete on lower tablet weight, higher tensile strength, faster disintegration, or improved blend uniformity.

Coating systems

LYBALVI uses multiple tablet strengths with distinct visual identification. A ready-to-use coating system can reduce:

• Color-matching work
• Batch-to-batch appearance variation
• Coating development time
• Solvent and process optimization
• Supply-chain complexity

Color consistency has commercial value because dose-strength confusion is a material risk in psychiatric medicines.

Supply-chain opportunities

The product uses widely available excipients, so supply differentiation must come from:

• Dual sourcing
• Regional manufacturing
• Regulatory documentation
• Low extractables and leachables risk
• Consistent particle-size distribution
• Technical support for scale-up
• Reliable qualification packages for ANDA sponsors

Suppliers that provide formulation support and regulatory data are better positioned than commodity suppliers competing only on price.

How does LYBALVI compare with olanzapine monotherapy?

Attribute	LYBALVI	Olanzapine monotherapy
Active ingredients	Olanzapine plus samidorphan	Olanzapine
Dose structure	Four fixed-dose strengths	Multiple dosage forms and strengths
Weight-gain proposition	Designed to reduce olanzapine-associated weight gain	No samidorphan component
Formulation complexity	Higher because of low-dose samidorphan distribution	Lower
Generic development	Requires dual-active bioequivalence and content uniformity	More established
Excipient opportunity	Functional excipients, blend control, coating differentiation	Cost reduction and conventional tablet optimization
Patent exposure	Combination, method, and formulation issues	Mature generic landscape

LYBALVI’s commercial case depends on whether the reduction in weight gain supports a premium over generic olanzapine. The fixed-dose product has greater formulation and patent complexity, but that same complexity can create a period of differentiated pricing and delay direct generic substitution.

What is the revenue exposure and competitive outlook for LYBALVI?

The main revenue risk is substitution by generic olanzapine, not only by a LYBALVI-equivalent product. Payers may compare the cost of LYBALVI with inexpensive olanzapine and reserve the combination for patients with clinically meaningful weight-gain concerns.

The competitive landscape includes:

• Generic olanzapine tablets
• Olanzapine orally disintegrating tablets
• Long-acting injectable antipsychotics
• Other atypical antipsychotics with different metabolic profiles
• Potential future fixed-dose or weight-management-oriented combinations

LYBALVI retains commercial value where prescribers prioritize metabolic tolerability and adherence. Its revenue exposure increases as payers impose step therapy, require prior authorization, or classify the product as a premium alternative to generic olanzapine.

Key Takeaways

• LYBALVI combines olanzapine with a fixed 10 mg dose of samidorphan across four strengths.
• The central excipient challenge is uniform distribution of low-dose samidorphan within an immediate-release tablet.
• Functional excipient grades, blend engineering, granulation, lubrication, and coating control are more commercially important than novel excipient identity.
• Generic development requires dual-active analytical methods, strength-specific dissolution, and robust content-uniformity controls.
• Patent risk may include fixed-dose composition, method-of-use, formulation, and manufacturing claims.
• FDA Orange Book listings and Paragraph IV litigation determine the practical generic-entry timeline.
• Excipient suppliers have the strongest opportunities in high-functionality direct-compression materials, ready-to-use coatings, technical support, and dual-source supply.
• The largest long-term commercial threat is substitution by low-cost generic olanzapine as well as direct LYBALVI-equivalent competition.

FAQs About LYBALVI Excipients and Commercial Opportunities

Can a generic LYBALVI use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the product meets pharmaceutical-equivalence, bioequivalence, quality, and safety requirements. The applicant must control the impact of any excipient change on dissolution, stability, tablet performance, and samidorphan content uniformity.

Is LYBALVI an extended-release formulation?

No. LYBALVI is an immediate-release oral tablet. Its formulation strategy centers on rapid disintegration, dissolution, blend uniformity, and stability rather than controlled-release polymer technology.[1]

Which excipient is most critical for LYBALVI bioequivalence?

No single excipient determines bioequivalence. Microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate can collectively affect tablet strength, disintegration, dissolution, and drug release. Process conditions may be as important as excipient selection.

Can a manufacturer commercialize only one LYBALVI strength?

Potentially, but a single-strength launch would limit prescribing and formulary coverage. The four-strength portfolio is commercially important because olanzapine dosing is titrated while samidorphan remains fixed at 10 mg.

Are biosimilars relevant to LYBALVI?

No. LYBALVI is a small-molecule oral combination, not a biologic. Competitive products would enter through the generic drug pathway, typically an ANDA under the Hatch-Waxman framework, rather than through the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2021). LYBALVI (olanzapine and samidorphan) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and Paragraph IV patent certifications. FDA.
4. DailyMed. (2024). LYBALVI: Olanzapine and samidorphan tablet, film coated. National Library of Medicine.